中文在线版电视剧免费观看,国产一级在线观看视频,欧美大片ppt免费大全

項目背景：

公司專注于傳染性疾病領域的創新藥物研發及商業化，致力于為中國和全球患者提供可負擔的高品質新型治療方案。
The company focuses itself in the development and commercialization of innovative drugs for infectious diseases, and is committed to providing affordable and high-quality new treatment solutions for patients in China and around the world.

公司生物醫藥采取“3I”戰略(創新Innovation、整合Integration和國際化Internationalization)，聯合中科院武漢病毒所和中科院上海藥物研究所新藥研發優勢，充分利用九州通已建立的商業化渠道優勢，使越來越多的創新藥惠及大眾，推動我國藥品創新與服務的高質量發展。
adopts the "3I" strategy (Innovation, Integration and Internationalization). By combining the strength of Wuhan Institute of Virology and Shanghai Institute of Materia Medica (Chinese Academy of Sciences) in new drug R&D, and by making full use of the well-established commercial channels from JoinTown Pharmaceutical Group, JKT BioPharma will be able to ensure accessibility of the public to more and more innovative drugs, and to bring drug innovation and services in China to a higher level.